




ジクロフェナク Diclofenac


日本薬局方におけるカラム選定条件は、「*p*-オキシ安息香酸エチル、*p*-オキシ安息香酸プロピルの順に溶出し、その分離度が5以上あるものを用いる」と定められています。また、局方ではカラム長 25 cm の例が紹介されていますが、CAPCELL PAK C₁₈ MGII は 7.5 cm のカラムにて分離度は 8.6 を達成し、大幅な時間短縮を可能とします。

The Japanese Pharmacopoeia (JP) requires a column to elute compounds in the order of ethyl *p*-hydroxybenzoate and propyl *p*-hydroxybenzoate, with a resolution value of 5 or greater between the two compounds. Although JP shows an example with a 25-cm column, a 7.5-cm column of CAPCELL PAK C₁₈ MGII showed a resolution of 8.6, saving time to a large extent.






1. Diclofenac



2. Ethyl *p*-hydroxybenzoate



3. Propyl *p*-hydroxybenzoate

[HPLC Conditions]

Column : CAPCELL PAK C₁₈ MGII S5 ; 4.6 mm i.d. x 150 mm
Mobile phase : 0.12 vol% CH₃COOH / CH₃OH = 3 / 4
Flow rate : 0.9 mL/min
Temperature : 40 ° C
Detection : UV 240 nm
Inj. vol. : 20 µL
Sample dissolved in : Mobile phase (1000 µg/mL as diclofenac sodium)
1 µg/mL = 1 ppm